Archivio delle pubblicazioni

Pubblicazioni del Gruppo di Studio ALCARE

Questa è la lista aggiornata di tutte le pubblicazioni del gruppo. Se siete interessati a ricevere un “reprint”, potete richiederlo al Direttore Scientifico, Dr. Buccheri.

(1) Buccheri G, Violante B, Ferrigno D, Vola F, Curcio A, Rosso A et al. Mancanza di sinergismo fra radioterapia e chemio-immunoterapia nel trattamento del carcinoma polmonare a cellule d’avena. Rivista di Oncologia 1985; 4:1-9.

(2) Buccheri G, Violante B, Castellino R. Incisional recurrence of a lung neoplasm after an apparently curative lobectomy. Report of a case. Rivista di Oncologia 1985; 4:1-4.

(3) Buccheri G, Violante B, Sartoris AM, Ferrigno D, Vola F, Curcio A. Diagnostic value of a multiple bio-marker assay in carcinoma of the lung. Abstract Book , A 29. 1985. Ref Type: Abstract

(4) Bramardi AM, Buccheri G, Ferrigno D, Vola F, Curcio A. Comparative study of CEA, TPA, and CA-50 in patients with bronchogenic carcinoma. Bull.Eur.Physiopath.Respir. 22 (suppl 8), 98. 1986. Ref Type: Abstract

(5) Buccheri G, D’Angeli B, Vola F, Biggi A, Ferrigno D, Violante B et al. Role of 67-gallium whole body scintigraphy in the staging of lung cancer, with a comparison to thoracic computed tomography. Bull.Eur.Physiopath.Respir. 22 (suppl 8), 98. 1986. Ref Type: Abstract

(6) Buccheri G, Violante B, Curcio A, Ferrigno D, Vola F, Rosso A et al. Rilievi epidemiologici ed istopatologici su 396 casi di tumore del polmone. Min Pneum 1986; 25:1-7.

(7) Buccheri G, D’Angeli B, Vola F, Biggi A, Ferrigno D, Violante B et al. Is 67-gallium uptake a prognostic indicator in non-small cell lung cancer? Bull.Eur.Physiopath.Respir. 22 (suppl 8), 98. 1986. Ref Type: Abstract

(8) Buccheri G, Ferrigno D, Bramardi AM, Violante B. Colon cancer cell surface antigen (CA19-9) in the management of lung cancer: a comparison with carcinoembryonic antigen (CEA) and tissue polypeptide antigen (TPA). Bull.Eur.Physiopath.Respir. 22 (suppl 8), 98. 1986. Ref Type: Abstract

(9) Buccheri G, Ferrigno D, Curcio A, Vola F, Mattalia E. MACC (methotrexate, doxorubicin, cyclophosphamide and lomustine) versus cis-platinum and etoposide in the treatment of advanced non-small cell lung cancer. Chemioterapia 1986; 5(1):53-57.

(10) Buccheri G, Ferrigno D, Curcio A, Vola F, Perroni D, Marchetti G. Modalita combinata di trattamento del carcinoma polmonare a piccole cellule (immuno-chemio e radioterapia). Farmaci 1986; 10 (suppl 2):217-220.

(11) Buccheri GF, Violante B, Sartoris AM, Ferrigno D, Curcio A, Vola F. Clinical value of a multiple biomarker assay in patients with bronchogenic carcinoma. Cancer 1986; 57(12):2389-2396.

(12) Ferrigno D, Buccheri G, Vola F, Curcio A, Barberis P. Il carcinoma bronchiolo-alveolare: presentazione di 7 casi clinici e revisione della letteratura. Rivista di Oncologia 1986; 3:1-8.

(13) Marchetti G, Pelissero A, Russi E, Vanzo C, Buccheri G, Mazza R et al. Regressione totale di metastasi polmonari multiple da carcinoma vescicale dopo chemio e immunoterapia (TP1). Farmaci 1986; 10 (suppl 2):201.

(14) Vola F, Ferrigno D, Buccheri G, Violante B, Curcio A, Delfino MS et al. Rilievi clinico-epidemiologici su 194 casi di tumore del polmone. G I M T 1986; 40:11-16.

(15) Buccheri G, Ferrigno D, Violante B. Clinical value of tissue polyptide antigen (TPA) assay in lung cancer management. Am.Rev.Respir.Dis. 135 (4), A 72. 1987.  Ref Type: Abstract

(16) Buccheri G, Vola F, Ferrigno D, Curcio A, Violante B. Lack of clinical significance of gallium-67 uptake in non-small cell lung cancer. Eur J Respir Dis 1987; 71(5):356-361.

(17) Buccheri G, Ferrigno D, Curcio A, Vola F. How long patients with non-small cell lung cancer and stable disease (nonresponder patients) should be maintained on chemotherapy? Abstract Book , A 302. 1987. Ref Type: Abstract

(18) Buccheri G, Ferrigno D, Violante B, Vola F, Curcio A. Carbohydrate antigen 19-9 (CA19-9) assay has no clinical utility in lung cancer. Am.Rev.Respir.Dis. 135 (4), A 418. 1987. Ref Type: Abstract

(19) Buccheri G, Ferrigno D, Vola F, Curcio A. MACC chemotherapy for advanced non-small cell lung cancer: a 3-year experience with 92 patients. Abstract Book . 1987. Ref Type: Abstract

(20) Buccheri GF, Ferrigno D, Sartoris AM, Violante B, Vola F, Curcio A. Tumor markers in bronchogenic carcinoma. Superiority of tissue polypeptide antigen to carcinoembryonic antigen and carbohydrate antigenic determinant 19-9. Cancer 1987; 60(1):42-50.

(21) Curcio A, Ferrigno D, Buccheri G, Delfino MS, Vola F, Cecchini C. Il carcinoma bronchiale: osservazioni cliniche ed epidemiologiche. Min Pneum 1987; 4:255-265.

(22) Quaranta M, Vassallo G, Viglione G, Aricò A, Rivetti R, Marchetti G et al. Importante riduzione volumetrica di multiple metastasi polmonari da adenocarcinoma del retto dopo immunoterapia (TP-1, Serono). Recenti Progressi in Medicina 6 (suppl 1), 277. 1987. Ref Type: Abstract

(23) Buccheri G, Ferrigno D. Usefulness of tissue polypeptide antigen in staging, monitoring, and prognosis of lung cancer. Chest 1988; 93:565-569.

(24) Buccheri G, Vola F, Leone A, Ferrigno D, Curcio A, Rosso A et al. Yield of computed tomographies of thorax, abdomen, and head (whole-body CT) in the diagnosis of lung cancer spread. The European Respiratory Journal 1 (suppl 2), A 302. 1988. Ref Type: Abstract

(25) Buccheri G, Ferrigno D, Curcio A, Rosso A, Vola F, Mazza R. MACC chemotherapy does not improve the survival of patients with advanced lung cancer: results of a controlled study. Abstract Book . 1988. Ref Type: Abstract

(26) Buccheri G, Ferrigno D, Curcio A, Rosso A, Vola F, Mazza R. MACC chemotherapy does not improve the survival of patients with advanced lung cancer: results of a controlled study. The European Respiratory Journal 1 (suppl 2), A 243. 1988. Ref Type: Abstract

(27) Buccheri G, Delfino MS, Barberis P, Aschero L, Ferrigno D. Differential endoscopic findings of bronchial cancer (BC) histotypes. Lung Cancer 4 (suppl 1), A 58. 1988. Ref Type: Abstract

(28) Buccheri G, Ferrigno D, Curcio A, Vola F, Rosso A, Cecchini C. Continouing chemotherapy in nonresponding patients with advanced non-small cell lung cancer: preliminary results of a randomized prospective study. Am.Rev.Respir.Dis. 4, 288. 1988. Ref Type: Abstract

(29) Buccheri G, Rendine S, Parachini F, Piazza A, Mazza R. The relative value of CEA, TPA, and other clinical indicators of survival: results of a multivariate analysis on 311 patients with lung cancer. The European Respiratory Journal 1 (suppl 2), A 238. 1988. Ref Type: Abstract

(30) Buccheri G, Delfino MS, Barberis P, Aschero L, Ferrigno D. Lung cancer (LC) endobronchial presentations and correlations with cyto- hystologic yield. Lung Cancer 4 (suppl 1), A 58. 1988. Ref Type: Abstract

(31) Buccheri G, Ferrigno D, Vola F, Rosso A, Curcio A. Comparative value of CEA, TPA, and neuronenolase (NE) in small cell lung cancer (SCLC) management. Lung Cancer 4 (suppl 1), A 46. 1988. Ref Type: Abstract

(32) Camuzzini GF, Biggi A, Buccheri G, Leone A, Comino A, D’Angeli B et al. Possibilità applicative degli anticorpi monoclonali anti-CEA nella stadiazione della neoplasia polmonare. Abstract Book . 1988. Ref Type: Abstract

(33) Curcio A, Rendine S, Ferrigno D, Rosso A, Vola F, Buccheri G. Fattori di prognosi nel cancro polmonare: risultati di un’analisi multivariata. Giornale Italiano di Malattie del Torace 42, 344. 1988. Ref Type: Abstract

(34) Ferrigno D, Rendine S, Parachini F, Curcio A, Rosso A, Vola F et al. Il valore prognostico del CEA e del TPA nella valutazione iniziale del cancro polmonare. Abstract Book . 1988.Ref Type: Abstract

(35) Ferrigno D, Buccheri G, Vola F, Curcio A, Rosso A. Mancato miglioramento della sopravvivenza in pazienti con tumore polmonare inoperabile non a piccole cellule (NSCLC) dopo chemioterapia (regime MACC): risultati di uno studio controllato. Giornale Italiano di Malattie del Torace 42, 345. 1988. Ref Type: Abstract

(36) Perroni D, Bumma C, Grecchi GL, Buccheri G, Vola F, Ferrigno D et al. Valutazione della fattibilità di uno schema di polichemioterapia a scadenza settimanale (CEMOV-P) nel carcinoma polmonare a piccole cellule (CPPC) diffuso. Abstract Book . 1988. Ref Type: Abstract

(37) Perroni D, Grecchi GL, Bumma C, Buccheri G, Vola F, Ferrigno D et al. Polichemioterapia intensiva di breve durata a scadenza settimale nel carcinoma polmonare a piccole cellule (CPPC) diffuso. Abstract Book , A 450. 1988. Ref Type: Abstract

(38) Taviani M, Lo Casto RM, Ferrigno D, Buccheri G, Pescio G, Verna A et al. Il ruolo della mediastinoscopia nell’iter diagnostico della patologia toraco-mediastinica: analisi della casistica. Rassegna di Patologia dell’Apparato Respiratorio 1988; 4:121-124.

(39) Vola F, Ferrigno D, Curcio A, Buccheri G, Barberis P. Presentazione endoscopica del carcinoma bronchiale e sua correlazione con la resa cito-istologica dei prelievi endobronchiali. Giornale Italiano di Malattie del Torace 42, 351. 1988. Ref Type: Abstract

(40) Buccheri G, Ferrigno D, Vola F. Survival prediction from a multiple regression model in lung cancer. Abstract Book , P-0032. 1989. Ref Type: Abstract

(41) Buccheri G, Barberis P, Aschero L. Differential endoscopic findings of lung cancer (LC) histotypes. A study of 543 carcinomas. Abstract Book , A 281. 1989. Ref Type: Abstract

(42) Buccheri G, Parachini F, Perroni D, Grecchi GL, Bumma C. The carcinoembryonic antigen (CEA) assay in patients with breast cancer (BC). Cancer Chemotherapy and Pharmacology 23 (suppl 1), C 53. 1989. Ref Type: Abstract

(43) Buccheri G, Parachini F, Perroni D, Bumma C. Comparison of the tumor markers CA15-3, CA125, CA19-9 in breast cancer. Cancer Chemotherapy and Pharmacology 23 (suppl 1), C 53. 1989. Ref Type: Abstract

(44) Buccheri G, Ferrigno D, Vola F, Curcio A. Combination of chemotherapy with methrotexate, adriamycin, cyclophosphamide, and CCNU (MACC) for non-small cell lung cancer: 4-year experience with 92 patients. Oncology 1989; 46:212-216.

(45) Buccheri G, Ferrigno D, Biggi A, D’Angeli B, Quaranta M, Vassallo G et al. Anti-CEA monoclonal antibodies (MAbs) in the staging of lung cancer. Abstract Book , A 64. 1989. Ref Type: Abstract

(46) Buccheri G, Biggi A, D’Angeli B, Quaranta M, Vassallo G, Leone A. Scintigraphy with anti-CEA monoclonal antibodies (MAbs) in lung cancer (LC). Abstract Book , O-1153. 1989. Ref Type: Abstract

(47) Buccheri G, Parachini F, Perroni D, Bumma C. Tissue polypeptide antigen (TPA) correlates with tumor load in breast cancer (BC). Cancer Chemotherapy and Pharmacology 23 (suppl 1), C 53. 1989. Ref Type: Abstract

(48) Buccheri G, Cecchini C. TPA predictors in lung cancer: a study of 114 variables on 81 patients. The European Respiratory Journal 2 (suppl 2), 682. 1989. Ref Type: Abstract

(49) Buccheri G, Barberis P, Aschero L. Endoscopic presentations in lung cancer (LC). Abstract Book , A 278. 1989. Ref Type: Abstract

(50) Buccheri G, Vola F, Ferrigno D, Curcio A. Yield of total body GA-67 scintigraphy in the staging of non-small cell lung cancer. Tumori 1989; 75(1):38-42.

(51) Buccheri G, Rosso A, Ferrigno D, Vola F, Cecchini C, Castellino R. Polychemotherapy does prolong the survival of patients with advanced non-small cell lung cancer. A controlled study. Abstract Book , A 118. 1989. Ref Type: Abstract

(52) Buccheri G, Rosso A, Castellino R, Ferrigno D, Vola F, Cecchini C. MACC chemotherapy does prolong survival of patients with unresectable NSCLC. Abstract Book , P-0031. 1989.

(53) Buccheri G, Rendine S, Ferrigno D. Prognostic value of carcinoembryonic antigen and tissue polypeptide antigen in lung cancer. Results of multivariate analysis of survival. Abstract Book , A 274. 1989.

(54) Buccheri G, Biggi A, D’Angeli B, Quaranta M, Vassallo G, Leone A et al. Indium-111 anti-CEA monoclonal antibodies (MAbs) in diagnosis and staging of lung cancer. Abstract Book , A 132. 1989.

(55) Buccheri GF, Ferrigno D, Curcio A, Vola F, Rosso A. Continuation of chemotherapy versus supportive care alone in patients with inoperable non-small cell lung cancer and stable disease after two or three cycles of MACC. Results of a randomized prospective study. Cancer 1989; 63(3):428-432.

(56) Bumma C, Perroni D, Buccheri G, Curcio A, Ferrigno D, Grecchi GL et al. Polichemioterapia intensiva a scadenza settimanale con ciclofosfamide, methotrexate, vincristina, platino, ed etoposide (CEMOV-P) nel carcinoma polmonare a piccole cellule. In: Morino F, Caldarola L, Mussa A, Calderini P, Carretti D, Maltoni C, editors. Il ruolo della terapia chirurgica in oncologia. Torino: Monduzzi, 1989: 645-649.

(57) Cecchini C, Buccheri G, Ferrigno D. Aspetti endoscopici differenziali negli istotipi di carcinoma broncogeno. Rassegna di Patologia dell’Apparato Respiratorio 4 (suppl 1), 83. 1989.

(58) Cecchini C, Ferrigno D, Buccheri G. Prolungamento della sopravvivenza dopo polichemioterapia nel NSCLC: studio controllato. Rassegna di Patologia dell’Apparato Respiratorio 4 (suppl 1), 52. 1989.

(59) Cecchini C, Buccheri G, Ferrigno D. Aspetti endoscopici nel carcinoma polmonare; valutazione di 806 casi. Rassegna di Patologia dell’Apparato Respiratorio 4 (suppl 1), 84. 1989.

(60) Ferrigno D, Buccheri G, Rendine S. The prognostic value of CEA and TPA in the initial evaluation of lung cancer: results of a multivariate analysis of 312 patients. In: Motta G, editor. Lung cancer: advanced concepts and present status. Genova: IASLG, 1989: 179-188.

(61) Ferrigno D, Buccheri G, Leone A. Sindrome cerebellare paraneoplastica in corso di neoplasia polmonare. Caso clinico e revisione della letteratura. Min Pneum 1989; 28:43-46.

(62) Ferrigno D, Buccheri G. Endoscopic presentations in lung cancer: a study of 806 bronchoscopies. The European Respiratory Journal 2 (suppl 2), 638. 1989.

(63) Ferrigno D, Buccheri G. Differential endoscopic findings of bronchial histotypes. The European Respiratory Journal 2 (suppl 2), 826. 1989.

(64) Buccheri G, Biggi A, Ferrigno D, D’Angeli B, Quaranta M, Taviani M et al. Anti-CEA monoclonal antibodies (MABS) for lung cancer: staging. The European Respiratory Journal 3 (suppl 10), 108. 1990.

(65) Buccheri G, Biggi A, Ferrigno D, D’Angeli B, Quaranta M, Taviani M et al. Anti-CEA monoclonal antibody scan for lung cancer: detection. The European Respiratory Journal 3 (suppl 10), 201. 1990.

(66) Buccheri G, Ferrigno D, Perroni D. 6-drug weekly chemotherapy (CEMOV-P) for small cell lung cancer (SCLC). The European Respiratory Journal 3 (suppl 10), 401-402. 1990.

(67) Buccheri G, Ferrigno D, Vola F. CEA expression in lung cancer (LC): a study of 35 variables in 531 patients. The European Respiratory Journal 3 (suppl 10), 402. 1990.

(68) Buccheri G, Ferrigno D, Vola F. TPA expression in lung cancer (LC): a study of 35 variables in 531 patients. The European Respiratory Journal 3 (suppl 10), 401. 1990.

(69) Buccheri G, Ferrigno D, Rosso A, Vola F. Further evidence in favour of chemotherapy for inoperable non-small cell lung cancer. Lung Cancer 1990; 6:87-98.

(70) Buccheri G, Marino P, Preatoni A, Ferrigno D, Cori P, Marelli F et al. Soluble interleukin-2 receptors (SIL-2R): a new marker for lung cancer? The European Respiratory Journal 3 (suppl 10), 223-224. 1990.

(71) Bumma C, Perroni D, Buccheri G, Ferrigno D, Vola F, Rosso A et al. Cell kinetic-based polychemotherapy in small cell lung cancer. Abstract Book , 161. 1990.

(72) Ferrigno D, Buccheri G, Marino P, Preatoni A, Cori P, Rosti A et al. Recettori solubili per l’interleukina-2: una nuova classe di marcatori sierici per il tumore polmonare? Abstract Book , 136. 1990.

(73) Ferrigno D, Biggi A, Buccheri G, D’Angeli B, Camuzzini GF. Immunoscintigrafia con anticorpi monoclonali anti-CEA in pazienti con neoplasia polmonare. Abstract Book , 134. 1990.

(74) Ferrigno D, Buccheri G, Cecchini C, Marchetti G. Clinical value of a multiple biomarker assay (CEA,TPA,NSE) in patients with SCLC. G I M T 1990; 44:135-140.

(75) Marino P, Buccheri G, Preatoni A, Ferrigno D, Cori P, Rosti A et al. Soluble interleukin-2 receptor: a new prognostic marker in lung cancer. J Nucl Med Allied Sci 1990; 34(4 Suppl):151-154.

(76) Biggi A, Buccheri G, Ferrigno D, Viglietti A, Farinelli MC, Comino A et al. Detection of suspected primary lung cancer by scintigraphy with indium-111-anti-carcinoembryonic antigen monoclonal antibodies (type FO23C5). J Nucl Med 1991; 32:2064-2068.

(77) Buccheri G, Ferrigno D. Tissue polypeptide antigen (TPA) is a powerful prognostic indicator in lung cancer (LC). The European Respiratory Journal 4 (suppl 14), 187. 1991.

(78) Buccheri G, Marino P, Preatoni A, Ferrigno D, Moroni GA. Soluble interleukin 2 receptor in lung cancer. An indirect marker of tumori activity? Chest 1991; 99:1433-1437.

(79) Buccheri G, Ferrigno D, Marino P, Preatoni A. Soluble interleukin-2 receptors (sIL-2R) in lung cancer. The European Respiratory Journal 4 (suppl 14), 173. 1991.

(80) Buccheri G, Ferrigno D. Tissue polypeptide antigen (TPA) has a great prognostic capability in lung cancer (LC). Eur.J.Cancer suppl 2, 267. 1991.

(81) Buccheri G, Ferrigno D. Tissue polypeptide antigen (TPA) and prognosis of lung cancer (LC). Chest 100 (suppl), 88. 1991.

(82) Buccheri G, Ferrigno D. Tissue polypeptide antigen (TPA) has a great prognostic capability in lung cancer (LC). Lung Cancer , 47. 1991.

(83) Buccheri G, Ferrigno D. Serum ferritin levels in lung cancer. The European Respiratory Journal 4 (suppl 14), 173. 1991.

(84) Buccheri G, Ferrigno D, Vola F, Rosso A. Prognostic factors in squamous cell lung cancer (SCLC): a study of 360 patients. The European Respiratory Journal 4 (suppl 14), 173-174. 1991.

(85) Buccheri G, Ferrigno D, Vola F, Rosso A. Multivariate survival analysis of 360 patients with squamous cell lung cancer (SCLC). Eur.J.Cancer suppl 2, 182. 1991.

(86) Buccheri G, Ferrigno D, Vola F, Rosso A. Multivariate survival analysis of 360 patients with squamous cell lung cancer (SCLC). Lung Cancer , 46. 1991.

(87) Buccheri G, Vola F, Ferrigno D. Quality of life evaluation in lung cancer (LC). Eur.J.Cancer suppl 2, 303. 1991.

(88) Buccheri G, Vola F, Ferrigno D. Quality of life evaluation in lung cancer. Lung Cancer , 175. 1991.

(89) Buccheri G, Vola F, Ferrigno D. Quality of life assessment during lung cancer (LC) treatment. Chest 100 (suppl), 87. 1991.

(90) Buccheri G, Rosso A, Ferrigno D, Vola F. Chemotherapy with MACC and lonidamine (LND) in unresectable NSCLC: a phase II study. Lung Cancer , 104. 1991.

(91) Buccheri G, Rosso A, Ferrigno D, Vola F. Chemotherapy with MACC and lonidamine (LND) in unresectable NSCLC: a phase II study. Eur.J.Cancer (suppl 2), 179. 1991.

(92) Buccheri G, Barberis P, Delfino MS. Diagnostic, morphologic, and histopathologic correlates in bronchogenic carcinoma. A review of 1045 bronchoscopic examinations. Chest 1991; 99:809-814.

(93) Buccheri G. Chemotherapy and survival in non-small cell lung cancer. The old ‘vexata questio’. Chest 1991; 99:1328-1329.

(94) Buccheri G, Biggi A, Ferrigno D, Leone A, D’Angeli B, Quaranta M et al. Anti-CEA immunoscintigraphy versus computed tomography (CT) in lung cancer (LC) staging. Eur.J.Cancer suppl 2, 276. 1991.

(95) Buccheri G, Biggi A, Ferrigno D, Leone A, D’Angeli B, Quaranta M et al. Anti-CEA immunscintigraphy versus computed tomography (CT) in lung cancer (LC) staging. Lung Cancer , 46. 1991.

(96) Buccheri G, Vola F, Ferrigno D. Assessing quality of life in patients with lung cancer (LC). The European Respiratory Journal 4 (suppl 14), 186. 1991.

(97) Ferrigno D, Buccheri G, Marino P, Preatoni A. Soluble interleukin-2 receptors (sIL-2R) in lung cancer. Chest 100 (suppl), 40. 1991.

(98) Ferrigno D, Buccheri G. Synchronous pulmonary and renal cancer [letter; comment]. Chest 1991; 100(2):587.

(99) Ferrigno D, Buccheri G. Serum levels of ferritin in patients with lung cancer. Lung Cancer , 13. 1991.

(100) Ferrigno D, Buccheri G. Serum levels of ferritin in patients with lung cancer. Eur.J.Cancer suppl 2, 266. 1991.

(101) Ferrigno D, Buccheri G, Marino P, Preatoni A. Soluble interleukin-2 receptor (sIL-2R) in serum of patients with lung cancer (LC). Eur.J.Cancer suppl 2, 267. 1991.

(102) Ferrigno D, Buccheri G. Chemioterapia e sopravvivenza del tumore polmonare non apiccole cellule inoperabile: un problema tutt’ora aperto? Rassegna di Patologia dell’Apparato Respiratorio 1991; 6:157-160.

(103) Marino P, Preatoni A, Buccheri G, Ferrigno D, Fruttero A. Increased levels of soluble interleukin-2 receptors in supernatants from peripheral blood mononuclear cells of patients with lung cancer. Eur J Cancer 1991; 27:1712.

(104) Marino P, Fruttero A, Preatoni A, Bossi B, Ferrigno D, Buccheri G. Inadequate T-cell help and increased concentration of IL-2 receptor in lung cancer. The European Respiratory Journal 4 (suppl 14), 187. 1991.

(105) Marino P, Preatoni A, Pravettoni G, Ferrigno D, Buccheri G. Evaluation of TPS-IRMA in lung cancer. A preliminary report. Chest 100 (suppl), 88. 1991.

(106) Marino P, Preatoni A, Pravettoni G, Ferrigno D, Buccheri G. Evaluation of TPS-IRMA in lung cancer. A preliminary report. The European Respiratory Journal 4 (suppl 14), 187. 1991.

(107) Marino P, Fruttero A, Preatoni A, Bossi B, Ferrigno D, Buccheri G. Inadequate T-cell help and increased concentration of IL-2 receptor in lung cancer. Chest 100 (suppl), 40. 1991.

(108) Vola F, Ferrigno D, Buccheri G, Rosso A. Tumore polmonare: fattori di rischio, diagnostica, e terapia. Med Subalp 1991; 1(2):16-17.

(109) Buccheri G, Vola F, Ferrigno D. Reliability and validity of a multiple-item questionnaire for patients with lung cancer. The European Respiratory Journal 5 (suppl 15), 340. 1992.

(110) Buccheri G. Mesothelioma:update. Abstract Book . 1992.

(111) Buccheri G, Vola F, Ferrigno D. Quality of life does not significantly worsen in patients on chemotherapy for inoperable non small-cell lung cancer. The European Respiratory Journal 5 (suppl 15), 448. 1992.

(112) Buccheri G, Vola F, Ferrigno D. Quality of life does not worsen during chemotherapy for inoperable non small-cell lung cancer. Chest 102 (suppl), 168s. 1992.

(113) Buccheri G, Vola F, Ferrigno D. Reliability and validity of a multiple-item questionnaire for patients with lung cancer. Chest 102 (suppl), 168s. 1992.

(114) Buccheri G, Ferrigno D. Brain-CT as a routine staging procedure for lung cancer: is it worthwhile? The European Respiratory Journal 5 (suppl 15), 337. 1992.

(115) Buccheri G, Ferrigno D. Brain-CT as a routine technique of lung cancer staging: is it worthwhile? Chest 102 (suppl), 169s. 1992.

(116) Buccheri G, Ferrigno D. Prognostic value of the tissue polyptide antigen in lung cancer. Chest 1992; 101:1287-1292.

(117) Buccheri G. Chemioterapia e tumore avanzato non apiccole cellule del polmone: davvero nessun progresso negli ultimi cinquant’anni? In: Pezza A, De Blasio F, editors. Highlights in pneumology. 1992: il cancro del polmone. Napoli: Poligrafica F.lli Ariello, 1992: 77-85.

(118) Buccheri G, Biggi A, Ferrigno D, D’Angeli B, Vassallo G, Leone A et al. Imaging lung cancer by scintigraphy with Indium-111 labeled F(ab’)2 fragments of the anticarcinoembryonic antigen monoclonal antibody FO23C5. Cancer 1992; 70:749-759.

(119) Buccheri G, Ferrigno D, Rosso A. MACC +/- Lonidamine for advanced NSCLC: preliminary results of a randomized study. Chest 102 (suppl), 169s. 1992.

(120) Buccheri G, Ferrigno D, Vola F. Utility of serial measurements of TPA during the follow-up of patients with lung cancer (LC). Chest 102 (suppl), 61s. 1992.

(121) Buccheri G, Ferrigno D, Vola F. Utility of serial measurements of TPA during the follow-up of patients with lung cancer. The European Respiratory Journal 5 (suppl 15), 224. 1992.

(122) Ferrigno D, Buccheri G. Serum ferritin levels in lung cancer patients [letter]. Eur J Cancer 1992; 28(1):241.

(123) Ferrigno D, Buccheri G. A comprehensive evaluation of serum ferritin levels in lung cancer patients. Lung Cancer 1992; 8:85-94.

(124) Ferrigno D, Buccheri G. Marcatori tumorali circolanti: quali applicazioni cliniche nel tumore polmonare? Argomenti di Oncologia 1992; 13:23-35.

(125) Ferrigno D, Buccheri G. Lumbar muscle metastasis from lung cancer–report of a case. Acta Oncol 1992; 31(6):680-681.

(126) Marino P, Buccheri G, Preatoni A, Ferrigno D, Luporini AC, Pravettoni G. Tissue polypeptide specific antigen (TPS) and objective response to treatment in solid tumors. Int J Biol Markers 1992; 7:65-67.

(127) Buccheri G, Ferrigno D. Serum protein and lung cancer prognosis. The European Respiratory Journal 6 (suppl. 17), 397s. 1993.

(128) Buccheri G, Biggi A, Ferrigno D, Leone A, Taviani M, Quaranta M. Anti-CEA immunoscintigraphy might be more useful than computed tomography in the preoperative thoracic evaluation of lung cancer. A comparison between planar immunoscintigraphy, single photon emission computed tomography (SPECT), and computed tomography. Chest 1993; 104(3):734-742.

(129) Buccheri G, Ferrigno D. Serum proteins and lung cancer prognosis. Chest 104, 119s. 1993.

(130) Buccheri G, Ferrigno D, Rosso A. A randomized trial of MACC chemotherapy with or without Lonidamine in advanced non-small cell lung cancer. The European Respiratory Journal 6 (suppl. 17), 129s. 1993.

(131) Buccheri G, Ferrigno D. Serum proteins and lung cancer prognosis. Eur.J.Cancer 29A, 244S. 1993.

(132) Buccheri G, Ferrigno D, Rosso A. A Phase II study of methotrexate, doxorubicin, cyclophosphamide, and lomustine chemotherapy and lonidamine in advanced non- small cell lung cancer. Cancer 1993; 72:1564-1572.

(133) Buccheri G, Biggi A, Ferrigno D, Leone A, Taviani M, Quaranta M. Anti-CEA immunoscintigraphy (IS) might be more useful than computed tomography (CT) in the pre-operative thoracic assessment of lung cancer (LC): a comparison between plan IS, single photo-emission CT (SPECT), and radiographic CT. The European Respiratory Journal 6 (suppl. 17), 294s. 1993.

(134) Buccheri G, Ferrigno D, Rosso A. A randomized trial of MACC chemotherapy with or without lonidamine in advanced non-small cell lung cancer. Eur.J.Cancer 29A, 160S. 1993.

(135) Buccheri G, Ferrigno D, Brunelli C, Tamburini M. Survival correlates of ratings of psychophysical well-being in lung cancer (LC). Chest 104, 45S. 1993.

(136) Buccheri G, Ferrigno D, Brunelli C, Tamburini M. Survival correlates of ratings of psycho-physical well-being in lung cancer (LC). Eur.J.Cancer 29A, 213S. 1993.

(137) Buccheri G, Biggi A, Ferrigno D, Leone A, Taviani M, Quaranta M. Anti-CEA immunoscintigraphy (IS) might be more useful than computed tomography (CT) in the pre-operative thoracic assessment of lung cancer (LC): a comparison between plan IS, single photon-emission CT (SPECT), and radiographic CT. Proc.Am.Soc.Clin.Oncol. 12, 339. 1993.

(138) Buccheri G, Ferrigno D, Vola F. Carcinoembryonic antigen (CEA), tissue polyptide antigen (TPA), and other prognostic indicators in the squamous cell carcinoma of the lung. Lung Cancer 1993; 10:21-33.

(139) Buccheri G, Ferrigno D. Can a single serum test provide similar or even superior diagnostic information that total body CT, or anti-CEA planar and SPECT immunoscintigraphy? Eur.J.Cancer 29A, 244S. 1993.

(140) Buccheri G, Vola F, Ferrigno D. Aspects of quality of life in patients with lung cancer: a three observer evaluation study. Int J Oncol 1993; 2:537-544.

(141) Buccheri G, Ferrigno D. Can a single serum test provide similar or even superior information than total body CT, or anti-CEA planar and SPECT scan? Value of measuring Tissue Polypeptide Antigen (TPA) in the pre-operative eveluation of lung cancer. Chest 104, 117S. 1993.

(142) Buccheri G, Biggi A, Ferrigno D, Leone A, Taviani M, Quaranta M. Anti-CEA immunoscintigraphy (IS) might be more useful than computed tomography (CT) in the pre-operative thoracic evaluation of lung cancer (LC): a comparison between planar IS, single photoemission CT (SPECT), and radiographic CT. Eur.J.Cancer 29A, 159S. 1993.

(143) Ferrigno D, Buccheri G, Rosso A. A randomized trial of MACC chemotherapy with or without Lonidamine in advanced non-small cell lung cancer. Proc.Am.Soc.Clin.Oncol. 12, 340. 1993.

(144) Biggi A, Buccheri G, Ferrigno D, Leone A, Quaranta M, Comino A et al. Immunoscintigraphy using monoclonal antibodies in primary lung cancer. Clinical applications of radiolabelled monoclonal antibodies in oncology. Wichtig Editore srl: Milan, 1994: 61-96.

(145) Buccheri G, Ferrigno D, Biggi A. Staging lung cancer with anti-CEA monoclonal antibody scintigraphy. The European Respiratory Journal 7 (suppl. 18), 61s. 1994.

(146) Buccheri G, Ferrigno D. Prognostic significance of the serum protein content in lung cancer (LC). Lung Cancer 11 (Suppl. 1), 25. 1994.

(147) Buccheri G, De Blasio F. La chemioterapia per il tumore polmonare non a piccole cellule. In: Pezza A, De Blasio F, editors. Il tumore del polmone. Napoli (Italy): Ariello Editore, 1994: 161-178.

(148) Buccheri G, Biggi A, Leone A, Taviani M, Quaranta M, Vassallo G. Anti-CEA immunoscintigraphy in the pre-operative thoracic assessment of lung cancer: a comparison with CT. In: Motta G, editor. Lung Cancer. Frontiers in Science and Treatment. Genoa (Italy): Grafica L.P., 1994: 165-179.

(149) Buccheri G, Ferrigno D, Biggi A. Staging potential of the anti-CEA monoclonal antibody scintigraphy in lung cancer. Proc.Am.Soc.Clin.Oncol. 13, 340. 1994.

(150) Buccheri G, Ferrigno D. Prognostic factors in lung cancer: tables and comments. Eur Respir J 1994; 7(7):1350-1364.

(151) Buccheri G, Ferrigno D. Can a blind serum test accurately diagnose changes of lung cancer disease status, or even anticipate them? The European Respiratory Journal 7 (suppl. 18), 267s. 1994.

(152) Buccheri G, Ferrigno D. Can a blind serum measurement of TPA accurately diagnose a change of disease status, or even to anticipate it? Lung Cancer 11 (Suppl. 1), 42. 1994.

(153) Buccheri G, Ferrigno D. Prognostic significance of the serum protein content in lung cancer (LC). The European Respiratory Journal 7 (suppl. 18), 389s. 1994.

(154) Buccheri G. Chemotherapy and survival in non-small cell lung cancer: Three years later. Chest 1994; 106:990-992.

(155) Buccheri G, Ferrigno D. Karnofsky and ECOG performance status in lung cancer: equivalence, construct validity, and predictive validity. Lung Cancer 11 (Suppl. 1), 87. 1994.

(156) Buccheri G. Platinum-based chemotherapy for inoperable non-small cell lung cancer: a real therapeutic progress? Lung Cancer 1994; 11:115-117.

(157) Buccheri G, Biggi A, Ferrigno D. Anti-CEA monoclonal antibody scintigraphies in lung cancer. Lung Cancer 11 (Suppl. 2), 86-87. 1994.

(158) Buccheri G, Ferrigno D. Clinical effects of high-dose medroxyprogesterone acetate (MPA) in anorexic patients with advanced lung cancer (LC). Lung Cancer 11 (Suppl. 1), 87. 1994.

(159) Buccheri G, Ferrigno D. A randomised trial of MACC chemotherapy with or without lonidamine in advanced non-small cell lung cancer. Eur J Cancer [A] 1994; 30A:1424-1431.

(160) Buccheri G, Ferrigno D. Karnofsky and ECOG performance status in lung cancer: equivalence, construct validity, and predictive validity. The European Respiratory Journal 7 (suppl. 18), 136s. 1994.

(161) Ferrigno D, Buccheri G, Biggi A. Serum tumour markers in lung cancer: history, biology and clinical applications. Eur Respir J 1994; 7(1):186-197.

(162) Ferrigno D, Buccheri G. Convegni e congressi: trattamento del carcinoma polmonare non a piccole cellule: questioni aperte e controversie. Med Subalp 1994; 4(4):21-22.

(163) Ferrigno D, Buccheri G. Karnofsky and ECOG performance status in lung cancer: equivalence, construct validity, and predictive validity. Proc.Am.Soc.Clin.Oncol. 13, 326. 1994.

(164) Ferrigno D, Buccheri G, Biggi A. Staging potential of the anti-CEA monoclonal antibody scintigraphy in lung cancer. Lung Cancer 11 (Suppl. 1), 71. 1994.

(165) Ferrigno D, Buccheri G. Cranial computed tomography as a part of the initial staging procedures for patients with non-small-cell lung cancer. Chest 1994; 106:1025-1029.

(166) Buccheri G, Ferrigno D. The tissue polypeptide antigen serum test in the preoperative evaluation of non-small cell lung cancer: Diagnostic yield and comparison with conventional staging methods. Chest 1995; 107:471-476.

(167) Buccheri G, Ferrigno D. Cancer familiarity has no practical meaning in lung cancer (LC) management: results of a large prospective study. The European Respiratory Journal 8 (suppl. 19), 478s. 1995.

(168) Buccheri G, Ferrigno D. Cancer familiarity has no practical meaning in lung cancer (LC) management: results of a large prospective study. Eur.J.Cancer 31A (Supplement 5), 222s. 1995.

(169) Buccheri G, Ferrigno D. The MVP regimen could be less active and toxic than previously described: a divergent report on non-small cell lung cancer. Eur.J.Cancer 31A (Supplement 5), 227s. 1995.

(170) Buccheri G, Ferrigno D. The MVP regimen for non-small cell lung cancer could be less active and toxic than previously described: a divergent report. The European Respiratory Journal 8 (suppl. 19), 135s. 1995.

(171) Buccheri G. The patient’s perception of his own quality of life affects the prognosis of lung cancer. Supp Care Oncol 1995; 16:11-13.

(172) Buccheri G. First International Lung Cancer Conference: Non-Small-Cell Lung Cancer. Open questions and controversies. Monaldi Arch Chest Dis 1995; 50(3):239-241.

(173) Buccheri G. Meeting summary: Cuneo Lung Cancer Study Group First International Lung Cancer Conference: open questions and controversies. Lung Cancer 1995; 12:105-108.

(174) Buccheri G, Ferrigno D, Borelli M, Perona F, Marchetti G, Fillini C et al. Self-exandable metallic stent for superior vena cava syndrome: a safe and effective treatment. Eur.J.Cancer 31A (Supplement 5), 183s. 1995.

(175) Buccheri G. Cuneo Lung Cancer Study Group. First International Lung Cancer Conference: non-small cell lung cancer: open questions and controversies. Lung Cancer 1995; 12(1-2):105-108.

(176) Buccheri G, Ferrigno D. Digital clubbing (DC) has no practical implications in lung cancer (LC): results of a large prospective study. The European Respiratory Journal 8 (suppl. 19), 375s. 1995.

(177) Buccheri G, Ferrigno D, Ginardi C. Pre-thrombotic state is a strong unfavourable indicator of lung cancer (LC) prognosis: results from a prospective study. The European Respiratory Journal 8 (suppl. 19), 478s. 1995.

(178) Buccheri G, Ferrigno D. Monitoring lung cancer with tissue polyptide antigen: an ancillary, profitable serum test to evaluate treatment response and posttreatment disease status. Lung Cancer 1995; 13:155-168.

(179) Buccheri G, Ferrigno D. Digital clubbing (DS) has no practical implications in lung cancer (LC): results of a large prospective study. Eur.J.Cancer 31A (Supplement 5), 227s. 1995.

(180) Buccheri G, Ferrigno D, Ginardi C. Pre-thrombotic state is a strong unfavorable indicator of lung cancer (LC) prognosis: results from a prospective study. Eur.J.Cancer 31A (Supplement 5), 221s. 1995.

(181) Buccheri G, Ferrigno D, Borelli M, Perona F, Fillini C, Ferro C. Self-expandable metallic stent for superior vena cava syndrome: a safe and effective treatment. The European Respiratory Journal 8 (suppl. 19), 529s. 1995.

(182) Buccheri GF, Ferrigno D, Tamburini M, Brunelli C. The patient’s perception of his own quality of life might have an adjunctive prognostic significance in lung cancer. Lung Cancer 1995; 12(1-2):45-58.

(183) Ferrigno D, Buccheri G. Assaying lactate dehydrogenase (LDH) in lung cancer (LC): results from a large prospective study. Eur.J.Cancer 31A (Supplement 5), 263s. 1995.

(184) Ferrigno D, Buccheri G. Does a positive brain CT reflect brain metastases? Reply. Chest 1995; 108:296.

(185) Ferrigno D, Buccheri G, Camilla T. Prognosis and lung cancer: the contribution of plasma proteins. Oncol Rep 1995; 2:637-641.

(186) Ferrigno D, Buccheri G. Trattamento del carcinoma polmonare non a piccole cellule: questioni aperte e controversie. Riv Tuberc Mal App Resp 1995; 27(1):99-100.

(187) Ferrigno D, Buccheri G. Clinical applications of serum markers for lung cancer. Respir Med 1995; 89:587-597.

(188) Ferro C, Scarrone A, Borelli M, Buccheri G, Ferrigno D, Marchetti G et al. Trattamento della sindrome della vena cava superiore con stent metallici. Esperienza preliminare. La Radiologia Medica 1995; 90(4):457-462.

(189) Ferro C, Scarrone A, Borrelli M, Buccheri G, Ferrigno D, Marchetti G et al. Treatment of superior vena cava syndrome by metal stents. Preliminary experience. Radiol Med (Torino ) 1995; 90(4):457-462.

(190) Lequaglie C, Ravasi G, Buccheri G, Ferrigno D, Maioli C, Marino P. Cyfra 21-1 compared with TPA in lung cancer – Results of a multicentric study. Chest 108 (Supplement), 198s. 1995.

(191) Marino P, Preatoni A, Cantoni A, Buccheri G. Single-agent chemotherapy versus combination chemotherapy in advanced non-small cell lung cancer: a quality and meta-analysis study. Lung Cancer 1995; 13:1-12.

(192) Buccheri G, Biggi A, Ferrigno D, Quaranta M, Leone A, Vassallo G et al. Anti-CEA immunoscintigraphy and computed tomographic scanning in the preoperative evaluation of mediastinal lymph nodes in lung cancer. Thorax 1996; 51:359-363.

(193) Buccheri G. Is there a standard treatment for locally advanced non-small cell lung cancer? [editorial]. Chest 1996; 109(4):864-866.

(194) Buccheri G, Ferrigno D, Tamburini M. Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution. Eur J Cancer 1996; 32A(7):1135-1141.

(195) Buccheri G, Ferrigno D. Mental depression and Lung Cancer (LC): a new powerful prognostic indicator. The European Respiratory Journal 9(Supplement 23), 307S. 1996.

(196) Buccheri G. Esiste una terapia “standard” per il carcinoma polmonare non a piccole cellule localmente avanzato? Pneumorama II[5], 4-6. 1996. Monza (MI), Midia srl.

(197) Buccheri G, Jett JR. Management of small cell lung cancer: current understanding and future prospects. Pulmonary Perspectives 1996; 13(1):6-8.

(198) Buccheri G, Ferrigno D. Therapeutic options for regionally advanced non-small cell lung cancer. Lung Cancer 1996; 14(2,3):281-300.

(199) Buccheri G, Ferrigno D. Lung Cancer (LC) in the elderly: clinical features and outcome. The European Respiratory Journal 9(Supplement 23), 373S. 1996.

(200) Buccheri G, Ferrigno D. Lung Cancer (LC) trends in an Alpine Area of northwest Italy: something changes over time, but not its dreadful prognosis. The European Respiratory Journal 9 (Supplement 23), 233S. 1996.

(201) Ferrigno D, Buccheri G. Is the MVP regimen less active than previously described? Results of a phase II study in advanced non-small cell lung cancer. Acta Oncol 1996; 35(4):435-439.

(202) Ferrigno D, Buccheri G. Applicazioni cliniche dei marcatori circolanti nel tumore del polmone. Eur Resp News 1996; 4(4):25-27.

(203) Buccheri G, Ferrigno D, Ginardi C, Zuliani C. Haemostatic abnormalities in lung cancer: prognostic implications [see comments]. Eur J Cancer 1997; 33(1):50-55.

(204) Buccheri G, Ferrigno D. Metastatic patterns in lung cancer: Prognostic implication. Lung Cancer 18[Supplement 1], 179. 1997.

(205) Buccheri G, Ferrigno D. Esiste una terapia “standard” per il carcinoma polmonare non a piccole cellule localmente avanzato? Med Subalp 1997;(3):19.

(206) Buccheri G. Immunoscintigraphy in the diagnosis and staging of lung cancer. Lung Cancer 18[Supplement 2], 99. 1997.

(207) Buccheri G, Ferrigno D. Randomized trial of platin (MVP) vs. non-platin-chemotherapy (MACC) in non-small cell lung cancer: a negative report from the Cuneo Lung Cancer Study Group (CuLCaSG). Lung Cancer 18[Supplement 1], 7. 1997.

(208) Buccheri G, Ferrigno D. The use of surrogate questionnaires for patients with lung cancer: A study of the cuneo lung cancer study group. Lung Cancer 18[Supplement 1], 222. 1997.

(209) Buccheri G, Ferrigno D. The use of surrogate questionnaires for the evaluation of chemotherapy: a study of the Cuneo lung cancer study group. The European Respiratory Journal 10[Supplement 25], 115S. 1997.

(210) Buccheri G, Camilla T, Ferrigno D. Copper and Zinc serum content in lung cancer: Abnormalities and clinical correlates. Lung Cancer 18[Supplement 1], 222. 1997.

(211) Buccheri G, Camilla T, Ferrigno D. Copper and zinc serum levels in lung cancer:abnormalities and clinical correlates. The European Respiratory Journal 10[Supplement 25], 380S. 1997.

(212) Buccheri G, Ferrigno D. Randomized trial of platin (MVP) vs. non-platin-chemotherapy (MACC) in non-small cell lung cancer: a negative report from the Cuneo Lung Cancer Study Group. The European Respiratory Journal 10[Supplement 25], 154S. 1997.

(213) Buccheri G, Ferrigno D. Efficacy of platinum-based regimes in non-small cell lung cancer. A negative report from the Cuneo Lung Cancer Study Group. Lung Cancer 1997; 18(1):57-70.

(214) Buccheri G, Ferrigno D, Biggi A. Nuclear medicine imaging in lung cancer: A plenty of possibilities (Review). Int J Oncol 1997; 10:847-855.

(215) Buccheri G. New prognostic factors in lung cancer. Monaldi Arch Chest Dis 1997; 52(6):535-539.

(216) Buccheri G, Ferrigno D. Chemioterapia con platino nel carcinoma polmonare non a piccole cellule: un reale progresso terapeutico? Pneumorama 1997; 3(8):53-56.

(217) Ferrigno D, Buccheri G, Biggi A. Applicazioni cliniche delle metodiche scintigrafiche nella diagnosi e nello staging del tumore polmonare. Rassegna di Patologia dell’Apparato Respiratorio 1997; 12(2):216-229.

(218) Marino P, Buccheri G, Ferrigno D. Liver metastases from lung cancer:value of biochemical tests. The European Respiratory Journal 10[Supplement 25], 381S. 1997.

(219) Marino P, Buccheri G, Ferrigno D. Liver metastases from lung cancer: Value of biochemical tests. Lung Cancer 18[Supplement 1], 154. 1997.

(220) Marino P, Buccheri G, Ferrigno D. Harmful effects of delaying the diagnosis of lung cancer. The European Respiratory Journal 10[Supplement 25], 411S. 1997.

(221) Buccheri G. I marcatori tumorali circolanti (MTC) nella diagnosi e nel followup dei pazienti con tumore del polmone. In: Motta G, editor. Postgraduate Course on the Staging of Lung Cancer – Working Book. Genova, Italy: NILCSA Committee, 1998.

(222) Buccheri G. Depressive reactions to lung cancer are common and often followed by a poor outcome. Eur Respir J 1998; 11(1):173-178.

(223) Buccheri G. “Highlights” dalla 2nd Cuneo Lung Cancer Conference. Eur Resp News 1998; 6(3):44-52.

(224) Buccheri G, Biggi A, Ferrigno D. Anti-CEA immunoscintigraphy in the mediastinal node preoperative assessment of lung cancer. In: Antypas G, editor. Proceedings at 3rd International Congress on Lung Cancer. Rhodes, 31October-4 November, 1998. Bologna: Monduzzi Editore, 1998: 43-49.

(225) Buccheri G. I Marcatori Tumorali. In: Bonsignre G, editor. Tumori del Polmone. Firenze: Boehringer Ingelheim Italia s.p.a., 1998: 23-27.

(226) Buccheri G, Ferrigno D. Nuovi farmaci per il tumore non a piccole cellule del polmone e loro impiego nella chemioterapia di seconda linea. Rassegna di Patologia dell’Apparato Respiratorio 1999; 14(5):458-469.

(227) Buccheri G. Circulating biomarkers for lung cancer. Ann Ital Chir 1999; 70(6):831-838.

(228) Buccheri G. Tumor Markers: Clinical Meaning and Use. In: Brambilla C, Brambilla E, editors. Lung Tumors. New York: Marcel Dekker, Inc., 1999: 435-452.

(229) Buccheri G, Ferrigno D. Terapie del carcinoma polmonare a piccole cellule (CPPC). In: Brusasco V, editor. Argomenti di Pneumologia. Torino: Centro Scientifico Editore, 1999: 129-134.

(230) Buccheri G, Ferrigno D. Istologia e classificazione T,N,M del carcinoma polmonare. In: Brusasco V, editor. Argomenti di Pneumologia. Torino: Centro Scientifico Editore, 1999: 81-92.

(231) Buccheri G, Ferrigno D. Sintomi, diagnosi e staging del carcinoma polmonare (CP). In: Brusasco V, editor. Argomenti di Pneumologia. Torino: Centro Scientifico Editore, 1999: 93-108.

(232) Buccheri G, Ferrigno D. Terapie del carcinoma polmonare non a piccole cellule (CPNPC). In: Brusasco V, editor. Argomenti di Pneumologia. Torino: Centro Scientifico Editore, 1999: 109-128.

(233) Buccheri G. Highlights from The Second Cuneo Lung Cancer Conference. Lung Cancer 1999; 23:77-90.

(234) Buccheri G, Ferrigno D. Epidemiologia, eziologia e prevenzione del carcinoma polmonare (CP). In: Brusasco V, editor. Argomenti di Pneumologia. Torino: Centro Scientifico Editore, 1999: 67-80.

(235) Ferrigno D, Buccheri G, Camilla T. Serum copper and zinc content in non-small cell lung cancer: abnormalities and clinical correlates. Monaldi Arch Chest Dis 1999; 54(3):204-208.

(236) Buccheri G, Ferrigno D. Prognostic value of stage grouping and TNM descriptors in lung cancer. Chest 2000; 117(5):1247-1255.

(237) Buccheri G, Ferrigno D. Serum biomarkers of non-neuron-endocrine origin in small-cell lung cancer: a 16-year study on carcinoembryonic antigen, tissue polypeptide antigen and lactate dehydrogenase. Lung Cancer 2000; 30(1):37-49.

(238) Buccheri G, Ferrigno D. Preoperative measurements of carcinoembryonic antigen may predict early recurrence in patients with resectable non-small cell lung cancer. Eur.Respir.J. 16(Supplement 31), 229s. 2000.

(239) Buccheri G, Ferrigno D. Serum biomarkers of non-neuron-endocrine origin in small cell lung cancer: A 16-year study on carcinoembryonic antigen (CEA), tissue polypeptide antigen (TPA), and lactate dehydrogenase (LDH). Lung Cancer 29 (Supplement 1), 190. 2000.

(240) Buccheri G, Ferrigno D. Serum biomarkers facilitate the recognition of early stage cancer and may guide the selection of surgical candidates: a studyof carcinoembryonic antigen (CEA) and tissue polypeptide antigen (TPA) in operable patients with non-small cell lung cancer (NSCLC). Eur.Respir.J. 16(Supplement 31), 229s-230s. 2000.

(241) Buccheri G, Ferrigno D. Vinorelbine in elderly patients with inoperable non-small cell lung cancer: A phase II study. Lung Cancer 29 (Supplement 1), 35. 2000.

(242) Buccheri G, Ferrigno D. Vinorelbine in elderly patients with inoperable non-small cell lung cancer: a phase II study. The European Respiratory Journal 16(Supplement 31), 338s. 2000.

(243) Buccheri G. The 9th World Conference on Lung Cancer. Riflessioni a margine di un evento scientifico e culturale di prima grandezza. Rassegna di Patologia dell’Apparato Respiratorio 2000; 14(4):336-338.

(244) Buccheri G, Ferrigno D. Vinorelbine in elderly patients with inoperable nonsmall cell lung carcinoma. Cancer 2000; 88(12):2677-2685.

(245) Buccheri G, Ferrigno D. Prognostic value of stage grouping and TNM descriptors in lung cancer. The European Respiratory Journal 16 (Supplement 31), 362s. 2000.

(246) Ferrigno D, Buccheri G. Second-line chemotherapy for recurrent non-small cell lung cancer: do new agents make a difference? Lung Cancer 2000; 29:91-104.

(247) Tamburini M, Buccheri G, Brunelli C, Ferrigno D. The difficult choice of chemotherapy in patients with unresectable non-small-cell lung cancer. Support Care Cancer 2000; 8(3):223-228.

(248) Buccheri G, Ferrigno D. Prognostic significance of blood coagulation tests in lung cancer. The European Respiratory Journal 18[Supplement 33], 231S. 2001.

(249) Buccheri G, Ferrigno D. Importance of weight loss definition in the prognostic evaluation on non-small cell lung cancer. The European Respiratory Journal 18[Supplement 33], 477S. 2001.

(250) Buccheri G, Ferrigno D. Marcatori citocheratinici del carcinoma broncogeno: conoscernze biologiche di base e principali applicazioni cliniche. Rassegna di Patologia dell’Apparato Respiratorio 16[5], 376-386. 2001.

(251) Buccheri G, Ferrigno D. Lung tumor markers of cytokeratin origin: an overview. Lung Cancer 2001 Dec ;34 Suppl 2:S65 -9 2001; 34 Suppl 2:S65-S69.

(252) Buccheri G. Problematiche diagnostiche del carcinoma polmonare. In: Donner CF, Sanguinetti CM, editors. Trattato Italiano di Pneumologia. Pisa: EDI-AIPO, 2001: 2303-2339.

(253) Buccheri G, Ferrigno D. Clinical characteristics, treatment, and prognosis of lung cancer elderly patients. The European Respiratory Journal 18[Supplement 33], 228S. 2001.

(254) Buccheri G, Ferrigno D. Serum biomarkers facilitate the recognition of early- stage cancer and may guide the selection of surgical candidates: A study of carcinoembryonic antigen and tissue polypeptide antigen in patients with operable non-small cell lung cancer. J Thorac Cardiovasc Surg 2001 Nov ;122 (5):891 -9 2001; 122:891-899.

(255) Buccheri G, Ferrigno D. Anthropometric measurements in non-small cell lung cancer. Eur.Respir.J. 18[Supplement 33], 229S. 2001.

(256) Buccheri G, Ferrigno D. Importance of weight loss definition in the prognostic evaluation of non-small-cell lung cancer. Lung Cancer 2001; 34(3):433-440.

(257) Buccheri G, Ferrigno D. Cytokeratin-derived markers of lung cancer. Expert Rev Mol Diagn 2001; 1(3):315-322.

(258) Ferrigno D, Buccheri G, Ricca I. Prognostic significance of blood coagulation tests in lung cancer. Eur Respir J 2001; 17(4):667-673.

(259) Ferrigno D, Buccheri G. Il tumore del polmone nell’anziano: aspetti clinici differenziali, trattamento, e prognosi. Rassegna di Patologia dell’Apparato Respiratorio 16[5], 335-342. 2001.

(260) Ferrigno D, Buccheri G. Anthropometric measurements in non-small-cell lung cancer. Support Care Cancer 2001 Oct ;9 (7 ):522 -7 2001; 9:522-527.

(261) Buccheri G, Biggi A, Ferrigno D, Francini A. 99mTC-tetrofosmin scintigraphy in lung carcinoma staging and follow-up evaluations. Cancer 2002; 94(6):1796-1807.

(262) Buccheri G. Vinorelbine in Elderly Patients with Inoperable Nonsmall Cell Lung Carcinoma (NSCLC. A Phase II Study. Author replay. Cancer 2002; 94(1):283.

(263) Buccheri G, Ferrigno D. Lung tumour markers in oncology practice: a study of TPA and CA125. Br J Cancer 2002 Nov 4;87 (10):1112 -8 2002; 87:1112-1118.

(264) De Marinis F, Conte PF, Rinaldi M, Chella A, Scanni A, Bongiorni E et al. Docetaxel in metastatic non-small cell lung cancer (NSCLC) patients who failed previous chemotherapy regimens. A first Italian muticenter phase II study (Taxit 206). Rassegna di Patologia dell’Apparato Respiratorio 2002; 17(5):377-384.

(265) Ferrigno D, Buccheri G. Metodiche di stadiazione del mediastino nel tumore polmonare non a piccole cellule. Rassegna di Patologia dell’Apparato Respiratorio 2002; 17(5):393-403.

(266) Ferrigno D, Giordano MC, Buccheri G. Prognostic significance of plasma D-dimer (DD) in lung cancer. Eur.Respir.J 20 (Supplement 38), 72S-73S. 2002.

(267) Ferrigno D, Giordano MC, Buccheri G. Prognostic significance of three tumor markers (CA125, CEA, and TPA) in lung cancer. Eur.Respir.J 20 (Supplement 38), 73S. 2002.

(268) Ferrigno D, Giordano MC, Buccheri G. Hematologic counts and their clinical correlates in 1201 newly diagnosed lung cancer patients. The European Respiratory Journal 20 (Supplement 38), 268S. 2002.

(269) Ferrigno D, Giordano MC, Buccheri G. Clinical correlates and prognostic significance of neuron specific enolase (NSE) in non-small cell lung cancer (NSCLC). The European Respiratory Journal 20 (Supplement 38), 73S. 2002.

(270) Vansteenkiste J, Buccheri G, Carney DN, Eberhardt W, Fontanini G, Jeremic B et al. Prognostic factors in nonsmall cell lung cancer. Eur Resp J 2002; 12(84):156-171.

(271) Buccheri G, Ferrigno D. The changing face of lung cancer: evidence from a cohort of patients diagnosed in a 14-year period of time. Lung Cancer 41[Supplement 2], S110. 2003.

(272) Buccheri G, Ferrigno D. Symptomatic pattern, alarm symptoms and diagnostic delay in a cohort of 1277 consecutive lung cancer patients. Lung Cancer 41[Supplement 2], S196. 2003.

(273) Buccheri G, Ferrigno D. Chemioterapia del tumore polmonare: certezze, promesse e disillusioni. Medico e paziente 8, 17-19. 2003.

(274) Buccheri G, Ferrigno D. Identifying patients at risk of early postoperative recurrence of lung cancer: a new use of the old CEA test. Ann Thorac Surg 2003;(75):973-980.

(275) Buccheri G, Torchio P, Ferrigno D. Clinical Equivalence of Two Cytokeratin Markers in Non-small Cell Lung Cancer: A Study of Tissue Polypeptide Antigen and Cytokeratin 19 Fragments. Chest 2003; 124(2):622-632.

(276) Buccheri G, Torchio P, Ferrigno D. Plasma levels of D-dimer in lung carcinoma: clinical and prognostic significance. Cancer 2003; 97(12):3044-3052.

(277) Buccheri G, Ferrigno D. Delay in specialist referral and clinical presentation in lung cancer: a 14-year study with 1277 patients. JAMA 2003; (submitted).

(278) Buccheri G, Ferrigno D, Giordano MC. Second line chemotherapy with paclitaxel in advanced non-small cell lung cancer, relapsing or refractory to a combination chemotherapy containing cis-platinum (P). Lung Cancer 41[Supplement 2], S228. 2003.

(279) Buccheri G, Ferrigno D. Family and personal history of cancer: how common and how clinically significant in lung cancer. Lung Cancer 41[Supplement 2], S109-S110. 2003.

(280) Buccheri G, Ferrigno D. Front-line weekly chemotherapy with gemcitabine for unfit and/or elderly patients with non-small cell lung cancer (NSCLC). Lung Cancer 41[Supplement 2], S228. 2003.

(281) Buccheri G, Ferrigno D, CuLCaSG-ALCASE Italia ONLUS. Cancro del polmone: ritardare a sospettarlo può costar caro! Giornale Italiano di Malattie del Torace 3, 188-190. 2003.

(282) Buccheri G. Certezze, promesse e disillusioni a Vancouver. Giornale Italiano di Malattie del Torace 5, 335-341. 2003.

(283) Buccheri G. Certezze, promesse e disillusioni a Vancouver. Rassegna di Patologia dell’Apparato Respiratorio 2003; 18(6):494-496.

(284) Ferrigno D, Buccheri G. Hematologic counts and clinical correlates in 1201 newly diagnosed lung cancer patients. Monaldi Arch Chest Dis 2003; 59(3):193-198.

(285) Ferrigno D, Buccheri G, Giordano C. Neuron-specific enolase is an effective tumour marker in non-small cell lung cancer (NSCLC). Lung Cancer 2003; 41(3):311-320.

(286) Ferrigno D, Buccheri G. Gli oncologi lanciano l’appello da Nizza. Giornale Italiano di Malattie del Torace 57[2], 113-115. 2003.

(287) Pujol J-L, Molinier O, Ebert W, Barlesi F, Daures JP, Buccheri G et al. CYFRA 21-1 is a prognostic determinant in non-small cell lung cancer: results of a meta-analysis in 2063 patients. Lung Cancer 41[Supplement 2], S203. 2003.

(288) Buccheri G, Ferrigno D. Lung cancer: clinical presentation and specialist referral time. Eur Respir J 2004; 24(6):898-904.

(289) Buccheri G, Ferrigno D, Barisone E, Noceti P. Fattori prognostici nel carcinoma polmonare non a piccole cellule in stadio avanzato. Minerva Pneumologica 43, 131-141. 2004.

(290) Buccheri G. Le ultime dal fronte della ricerca sul cancro del polmone: novità dal 40° meeting annuale dell’ASCO. Rassegna di Patologia dell’Apparato Respiratorio 19. 2004.

(291) Buccheri G, Ferrigno D, Giordano C. Cisplatin and vinorelbine remains a valid option for the front-line chemotherapy treatment of NSCLC. Anticancer Res 2004; 24:In press.

(292) Buccheri G, Ferrigno D, Giordano MC. Weekly chemotherapy with cisplatin/paclitaxel in the front-line treatment of NSCLC: a phase II study. Eur.Respir.J 24[Suppl 48]. 2004.

(293) Buccheri G. Cancro del polmone: da una malattia invisibile ad una sfida globale. Pneumorama 2, 24. 2004.

(294) Buccheri G. Raising lung cancer profile. Book of Abstract , 69. 2004.

(295) Buccheri G, Ferrigno D. Second-line weekly paclitaxel in patients with inoperable non-small cell lung cancer who fail combination chemotherapy with cisplatin. Lung Cancer 2004; 45(2):227-236.

(296) Ferrigno D, Buccheri G. Front-line weekly chemotherapy with gemcitabine for unfit patients with non-small cell lung cancer (NSCLC). Lung Cancer 2004; 45(3):373-380.

(297) Pujol JL, Molinier O, Ebert W, Daures JP, Barlesi F, Buccheri G et al. CYFRA 21-1 is a prognostic determinant in non-small-cell lung cancer: results of a meta-analysis in 2063 patients. Br J Cancer 2004.